Shilpa Medicare Ltd

Shilpa Medicare Ltd

Shilpa Medicare Limited (formerly known as Shilpa Antibiotics Limited) was incorporated as a Private Limited Company in November 20th 1987 and has been promoted by Vishnukant C Bhutada and his associates. Shilpa Medicare Limited (SML) is engaged in manufacturing of Active Pharmaceutical Ingredients (API) Formulation and Development service. The Company started its operations as API manufacturer way back in 1987 at Raichur Karnataka. The company started commercial production in November 1989. In November 1993 Shilpa Medicare Limited was converted into a Public Limited Company. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs including key products such as Capecitabine Gemcitabine Hydrochloride Axitinib Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA Europe Japan South Korea Russia Mexico Brazil and other emerging markets. While SML's underlying expertise is in the field of oncology it also derives revenue from sale of non-oncology APIs. With key products being Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.SML's product range includes over 44 oncology and non-oncology APIs. The Company's formulation product range consists of 16 injectable dosage forms 19 oral solid dosage forms under SML and 13 formulations under SML's wholly owned subsidiary Shilpa Therapeutics Private Limited.SML deals in high-quality Active Pharmaceutical Ingredients (APIs) Bulk drug Intermediates Formulations and Development service New Drug Delivery Systems Peptides / Biotech products and Specialty Chemicals etc. using sophisticated technology meticulously in order to comply with laid down international standards/specifications. SML is among the world's leading suppliers of Oncology/Non-Oncology APIs and intermediates.In year 1992 the company installed production facilities to manufacture sodium methoxide. During FY 2015 projects of five products transfer executed successfully other projects of eight products have been completed and ready for transfer to plant. Ten new molecules have been taken for development considering future demand.During FY15 as part of mobilization of resources for the purpose of expanding the operations of the Company fresh funds were raised by allotting 1764705 equity shares of Rs.2/- each to Tano Mauritius India FVCI II the existing member of the Company at a premium of Rs 423/-each on 15 May 2014 on preferential basis.During FY2016 the company after obtaining the approval of members at the 28th Annual General Meeting held on 28 September 2015 divided the face value of existing equity share of Rs.2/- into two equity shares of Re.1/- each fully paid-up with effect from the Record Date specified. Raichem Medicare Pvt Ltd. a subsidiary of Shilpa Medicare completed installation of all machineries during the FY 2015-2016 and recruited all the key personnel also commenced trial production in August 2015 after the Audit by External Consultant from Italy and started commercial production in December-2015. The subsidiary obtained the Drug Manufacturing license and GMP certificate and consent from pollution control board for operating the plant. In FY 16-17 Shilpa Medicare launched the generic versions of Vidaza Injection & Xeloda Tablets. During the year under review as part of mobilization of resources for the purpose of expanding the operations of the company fresh funds were raised by allotting 3025000 equity shares of Re.1/- each to TA FII Investors Limited at a premium of Rs.569/- each on 26 December 2016 on preferential basis.Pursuant to the order dated 24 November 2017 of Hon'ble National Company Law Tribunal Bangalore Bench the Navya Biologicals Private Limited has been merged with the Company with effect from 1 April 2016 being the appointed date for merger.During the year 2019 an amount of Rs 22.71 crore was invested into its wholly owned subsidiary Shilpa Therapeutics Pvt Ltd. (STPL) by way Loan to meet the project cost which is being set-up at Cherlapally Telangana.During the year 2019 the Company disinvested 24% of stake in Raichem Medicare Private Limited erstwhile Joint venture and sold to Joint Venture Partner ICE S.p.A.In FY 2019 the company incorporated Shilpa Pharma Inc. as a wholly owned subsidiary in United States of America. During the current FY 2019-20 the Company formed Sravathi Advance Process Technologies Private Limited to foray into the R&D activities of specific drug processes by roping prominent technocrats. It launched the Indian branded generic of Ibrutinib an anti-cancer drug under the brand name 'IBRUSHIL'. During the financial year 2019-2020 Shilpa launched Azacitidine covering the majority of European countries. It launched the first Indian Branded Generic of Lenvatinib Mesylate under the brand name Lenshil which is used for the treatment of differentiated thyroid cancer (DTC) and hepatocellular carcinoma. It sold 26% stake and exited from in Raichem Medicare Private Limited erstwhile Joint Venture in the month of June 2020. It incorporated Shilpa Albumin Private Limited and Shilpa Biologicals Private Limited as Wholly Owned Subsidiaries of the Company.In 2021 the Company launched a pediatric dose paracetamol oral thin film under the brand name 'Molshil' in strengths of 60 mg and 120 mg. It commissioned the State of Art Centralized Finished Dosages R&D Centre at Dabaspet near Bangalore. In 2021 Shilpa Biologicals Pvt Ltd (SBPL) a wholly owned subsidiary of Company signed an agreement with Dr. Reddy's Laboratories for production-supply of Sputnik V vaccine from its integrated Biologics R&D cum manufacturing center at Dharwad Karnataka. It formed Sravathi AI Technology Private Limited Shilpa Corporate Holdings Private Limited and Koanna Helathcare Cananda. In FY22 the Company received an approval from the Defence Research & Development Organization (DRDO) for the manufacture and sale of 2-DeoxyD-Glucose (2DG). It commissioned a combo line for ODF/TDS.During the year 2021-22 Shilpa Corporate holdings Private Limited an investment company has been formed as a wholly ownedsubsidiary which acquired 100% stake in FTF Pharma Private Limited an an integrated drug development company Koanaa Healthcare Canada Koanaa International FZ LLC (Dubai) Indo Biotech SDN. BHD Malaysia and so that all these companies have become as wholly Owned Subsidiaries. Further the Company acquired balance 25% equity shares of INM Technologies Private Limited and made a wholly owned subsidiary. INM Technologies Private Limited which is the wholly owned subsidiary of the Company holds 25% of its stake in INM Nuvent Paints Private Limited. The Company had disposed off the total stake in Loba Feinchemie Gmbh a step down subsidiary in Austria. In year 2022 the Company launched 12 formulations in India. The new launches were in the therapeutic areas of oncology non-oncology and products for the OTC market such as women hygiene vitamin supplements and an antioxidant green tea film. It commissioned new R&D center for polymer & peptide created separate wing for CDM0 with its scientific head.In 2022 the Shareholders of the Company have approved the Slump sale of Active Pharmaceutical Ingredient (API) Business of theCompany consisting of Unit-1 and Unit-2 situated at Raichur Karnataka to its wholly owned subsidiary `Shilpa Pharma Lifesciences Limited. The Company has duly executed the Business Transfer agreement with Shilpa Pharma Lifesciences Limited (Formerly known as Shilpa Corporate Holdings Private Limited) which is complete and effective from 30 June 2022.